Medindia

X

Reportlinker Adds Therapeutic Vaccines: the Global Market

Wednesday, April 7, 2010 Research News J E 4
Advertisement


NEW YORK, April 6 Reportlinker.com announces that a new market research report is available in its catalogue:

Therapeutic Vaccines: The Global Market

http://www.reportlinker.com/p0186000/Therapeutic-Vaccines-The-Global-Market.html

THIS REPORT:

Examine a period of dynamic growth in the therapeutic vaccines market with the expected rollout of some 20 products by 2010

Provide data on the global market for 2008, estimates for 2009, and forecasts, with compound annual growth rates (CAGRs), through 2014

Focus on companies poised to introduce products during the forecast period and how these introductions will play out in terms of the competitive environment

Explain how various approaches are being used to develop vaccines that boost the immune response to cancerous cells, and how they will add a powerful new component to standard cancer treatments.

Chapter- 1: INTRODUCTION

STUDY GOALS AND OBJECTIVES 1

REASONS FOR DOING THIS STUDY 1

INTENDED AUDIENCE 1

SCOPE OF REPORT 2

METHODOLOGY 2

INFORMATION SOURCES 3

AUTHOR'S CREDENTIALS 3

RELATED BCC REPORTS 3

BCC ONLINE SERVICES 3

DISCLAIMER 4

Chapter-2: SUMMARY

SUMMARY 5

SUMMARY TABLE THE WORLDWIDE MARKET FOR THERAPEUTIC VACCINES BY INDICATION, THROUGH 2014 ($ MILLIONS) 6

SUMMARY FIGURE THE WORLDWIDE MARKET FOR THERAPEUTIC VACCINES BY INDICATION, 2010-2014 6

Chapter-3: OVERVIEW

DEFINITION OF A THERAPEUTIC VACCINE 7

IMMUNE SYSTEM OVERVIEW: CAST OF CHARACTERS 7

B-CELLS, T-CELLS AND ANTIGEN-PRESENTING CELLS 7

B-Cells 8

T-Cells 8

Antigen-Presenting Cells 8

CELLULAR VERSUS HUMORAL IMMUNITY 8

INNOVATIVE APPROACHES TO VACCINE TECHNOLOGY 9

DNA VACCINES 9

CARBOHYDRATE VACCINES 9

THE ROLE OF ADJUVANTS 10

ATTRACTIVE FEATURES OF THERAPEUTIC VACCINES VERSUS OTHER CLASSES OF THERAPIES 11

TABLE 1 FEATURES OF THERAPEUTIC VACCINES VERSUS OTHER DRUG CLASSES 11

THERAPEUTIC VACCINES APPROVED FOR CLINICAL USE OR IN CLINICAL TRIALS 11

TABLE 2 THERAPEUTIC VACCINES IN CLINICAL TRIALS, ORDERED BY PHASE 11

TABLE 2 (CONTINUED) 12

TABLE 2 (CONTINUED) 13

TABLE 2 (CONTINUED) 14

TABLE 2 (CONTINUED) 15

TABLE 3 NUMBER OF THERAPEUTIC VACCINES IN CLINICAL TRIALS, BY PHASE 15

FIGURE 1 VACCINES IN CLINICAL TRIALS BY INDICATION, 2010 (%) 16

TABLE 4 VACCINES IN CLINICAL TRIALS BY TECHNOLOGY 16

TABLE 5 COMPANIES WITH THERAPEUTIC VACCINES IN CLINICAL TRIALS 17

Chapter-4: TECHNOLOGY OVERVIEW

TYPES OF THERAPEUTIC VACCINES 18

TABLE 6 COMPARISON OF AUTOLOGOUS VERSUS ALLOGENEIC VACCINES 18

TABLE 7 NUMBER OF ALLOGENEIC AND AUTOLOGOUS THERAPEUTIC VACCINES IN DEVELOPMENT BY PHASE 19

Chapter-5: PATENT EVALUATION

PATENT LENGTHS AND MARKET EXCLUSIVITY 20

TABLE 8 PATENT EXPIRATION DATES FOR THERAPEUTIC VACCINES IN LATE STAGES OF DEVELOPMENT 21

Chapter-6: PRODUCTS

ADDICTION VACCINES 22

TABLE 9 ADDICTION VACCINES IN DEVELOPMENT BY PHASE 23

TABLE 10 THE WORLDWIDE MARKET FOR ADDICTION VACCINES, THROUGH 2014 ($ MILLIONS) 23

COCAINE ADDICTION VACCINES 24

The Market for Cocaine Addiction Vaccines 24

TA-CD 25

NICOTINE ADDICTION VACCINES 26

The Market for Nicotine Addiction Vaccines 27

NicVAX 28

TABLE 11 NICOTINE ABSTINENCE RATE AT 12 MONTHS IN DIFFERENT STUDIES (%) 29

NIC002 29

TA-NIC 30

AUTOIMMUNE DISEASE VACCINES 31

TABLE 12 AUTOIMMUNE DISEASE VACCINES IN DEVELOPMENT BY PHASE 31

DIABETES (TYPE 1) 31

Diamyd (rhGAD65) 32

Diamyd (rhGAD65) (Continued) 33

BHT-3021 34

Tovaxin 35

TNFaKinoid 35

CANCER VACCINES 36

CANCER STATISTICS 37

U.S. Cancer Statistics 37

TABLE 13 INCIDENCE, MORTALITY, AND SURVIVAL RATES FOR COMMON CANCERS IN THE U.S., 2009 38

TABLE 14 CANCER PREVALENCE RATES IN THE U.S., 2006 (THOUSANDS) 39

Current Treatment Methods 39

Surgery 39

Radiation Therapy 40

Pharmaceutical Therapy 40

CANCER VACCINES: A NEW MODALITY OF CARE 41

The Primary Therapeutic Role for Cancer Vaccines 42

The Immune System and Cancer 43

Antigens: Their Role in Cancer Vaccines 43

Antigens Used in Cancer Vaccine Development 44

Carcinoembryonic Antigen 44

Ganglioside Molecules 44

Heat Shock Proteins 45

MART-1 45

Prostate-Specific Antigen 45

Sialyl Tn 46

Tyrosinase 46

MAGE 46

NY-ESO-1 46

MUC1 46

Vaccine Development: Strategies 47

Vaccine Development: ...(Continued) 48

A Summary of Two Approaches: Low-technology vs. High-technology 49

Vaccine Types 49

Antigen/Adjuvant Vaccines 49

Dendritic Cell Vaccines (DCs) 49

DNA and Viral Vector Vaccines 49

Idiotype Vaccines 50

Oncolytic Virus Vaccines 50

Whole Cell Tumor Vaccines 50

TABLE 15 TYPES OF VACCINES IN DEVELOPMENT FOR CANCER TREATMENT 51

The Long Road to Market 51

The Market for Cancer Vaccines 52

TABLE 16 ESTIMATED INITIAL U.S. MARKET OPPORTUNITY FOR CANCER VACCINES BY INDICATION 52

TABLE 17 WORLDWIDE MARKET FOR HUMAN CANCER VACCINES BY TYPE, THROUGH 2014 ($ MILLIONS) 53

TABLE 18 THE MARKET FOR HUMAN CANCER VACCINES, BY TECHNOLOGY (AUTOLOGOUS VERSUS ALLOGENEIC), WORLDWIDE, THROUGH 2014 ($ MILLIONS) 53

FIGURE 2 NUMBER OF AUTOLOGOUS VERSUS ALLOGENEIC CANCER VACCINES IN DEVELOPMENT, 2010 (%) 54

TABLE 19 THE WORLDWIDE MARKET FOR HUMAN CANCER VACCINES, BY INDICATION, THROUGH 2014 ($ MILLIONS) 54

CANCER VACCINES IN DEVELOPMENT 55

TABLE 20 CANCER VACCINES IN PHASE II OR LATER TRIALS BY PHASE 55

TABLE 20 (CONTINUED) 56

CANCER VACCINES APPROVED FOR USE ON THE WORLDWIDE MARKET 57

Melacine 57

Oncophage 58

Oncophage (Continued) 59

M-Vax 60

M-Vax (Continued) 61

CANCER VACCINES IN DEVELOPMENT 62

Provenge (APC8015, Sipuleucel-T) 62

TABLE 21 PROVENGE PHASE III CLINICAL TRIAL RESULTS 63

Provenge (Continued) 64

OncoVAX 65

OncoVAX (Continued) 66

MyVax 67

BiovaxId 68

BiovaxId (Continued) 69

Multikine 70

Multikine (Continued) 71

GSK1572932A 72

TABLE 22 EXPRESSION OF MAGE-A3 ANTIGEN BY TUMOR TYPE (%) 73

GSK2132231A 74

BLP25 Liposome Vaccine (Stimuvax) 74

BLP25 Liposome ... (Continued) 75

BLP25 Liposome ... (Continued) 76

TroVax 77

PR1 Peptide Vaccine 78

Allovectin-7 78

Allovectin-7 (Continued) 79

Belagenpumatucel-L (Lucanix) 80

GV1001 80

CB-10-01 81

MelCancerVac 81

GRNVAC1 82

DCVax-Brain 83

AGS-003 84

Glionix 84

CYT004-MelQbG10 85

CDX-110 (PF-04948568) 85

GI-4000 86

TABLE 23 OCCURRENCE OF RAS MUTATIONS IN VARIOUS SOLID TUMORS (%) 86

HyperAcute-Pancreas 86

HyperAcute Melanoma 87

HyperAcute-Lung 87

PEP223 88

IMA901 88

JX-594 89

Onyvax-P (ONY-P1) 89

Onyvax-P (ONY-P1) (Continued) 90

TG4010 (MVA-MUC1-IL2) 91

TG1042 (Ad-IFN?) 92

TG4001/R3484 (MVA-HPV-IL2) 92

Abagovomab 93

CV9103 93

AE37 94

NeuVax (E75) 95

ProstVac 95

INFECTIOUS DISEASE VACCINES 96

TABLE 24 INFECTIOUS DISEASE VACCINES IN DEVELOPMENT BY PHASE 96

HIV/AIDS 97

THE HIV INFECTION PROCESS 97

HIV TRANSMISSION 98

CONFUSION REGARDING THE PROPHYLACTIC VERSUS THERAPEUTIC ACTIVITY OF AIDS VACCINES 98

BARRIERS TO DEVELOPING AND TESTING AIDS VACCINES 99

Barriers to Developing ...(Continued) 100

WHAT HAS BEEN LEARNED 101

THE MARKET FOR AIDS VACCINES 102

HIV THERAPEUTIC VACCINES IN DEVELOPMENT 102

Results of Early Trials of HIV/AIDS Vaccines 103

AIDSVAX, the Most Advanced HIV Vaccine Candidate but with Mixed Results 104

The Failure of Merck's V520 Prophylactic and Therapeutic Vaccine 105

The Remune (AG1661, HIV-1 Immunogen) Saga 105

The Remune ... (Continued) 106

ALVAC-HIV (vCP1521), AIDSVAX Combination 107

HIV Vaccine 732461 108

Prophylactic and/or Therapeutic HIV Vaccine 108

Vacc-4x 108

DermaVir (LC002) 109

AGS-004 109

OTHER INFECTIOUS DISEASE VACCINES (OUTSIDE HIV) 110

HEPATITIS C 110

GI-5005 111

TG4040 (MVA-HCV) 111

IC41 112

NEUROLOGICAL DISEASE VACCINES 112

TABLE 25 NEUROLOGICAL DISEASE VACCINES IN DEVELOPMENT 112

THE MARKET FOR NEUROLOGICAL DISEASE VACCINES 113

Alzheimer's Disease Vaccine (AN-1792) (Discontinued) 113

ACC-001 114

CAD106 114

PARKINSON'S DISEASE VACCINE 115

OTHER DISEASE VACCINES 115

TABLE 26 OTHER DISEASE VACCINES IN DEVELOPMENT 115

CYT006-AngQb 115

Angiotensin Therapeutic Vaccine 116

Angiotensin ... (Continued) 117

Chapter-7: MAJOR COMPANIES AND MARKET SHARE

MARKET SHARE 118

TABLE 27 FORECASTED SALES AND MARKET SHARE OF COMPANIES INVOLVED IN THERAPEUTIC VACCINES, 2014 ($ MILLIONS/%) 118

COMPANY PROFILES 119

AFFIRIS 119

ANTIGENICS 120

ARGOS THERAPEUTICS 121

BAVARIAN NORDIC 121

BIOVEST INTERNATIONAL 122

CELLDEX THERAPEUTICS 123

CEL-SCI 123

CELTIC PHARMA 124

CUREVAC 124

CYTOS BIOTECHNOLOGY 125

DENDREON 126

DIAMYD MEDICAL 127

ELAN 127

GENEXINE 128

GERON 128

GLAXOSMITHKLINE 129

GLAXOSMITHKLINE - U.S. 129

GLOBEIMMUNE 130

KAEL 131

MERCK KGAA (MERCK SERONO) 131

NABI BIOPHARMACEUTICALS 132

NEWLINK GENETICS 132

NOVARTIS 133

NOVARTIS INSTITUTES FOR BIOMEDICAL RESEARCH 133

NOVARX 133

ONCOTHYREON 134

OXFORD BIOMEDICA 134

PFIZER 135

TRANSGENE 136

VACCINOGEN 137

VACCINOGEN - U.S. 137

VICAL 137

Vical (Continued) 138

Chapter-8: INTERNATIONAL ASPECTS AND REGULATORY ISSUES

MARKET BY REGION 139

TABLE 28 GLOBAL FORECAST FOR THERAPEUTIC VACCINES MARKET BY REGION, THROUGH 2014 ($ MILLIONS) 139

MARKET BY REGION (CONTINUED) 140

UNITED STATES 141

The FDA Modernization Act of 1997 141

Fast-track Status 141

Special Protocol Assessments 142

New Surveillance and Safety Requirements 142

Approvable Letters No More 143

Medicare 143

Other Healthcare Changes 144

EUROPEAN UNION 144

New Drug Approvals and Innovation 144

New Drug ... (Continued) 145

Drug Reimbursement and Reference Pricing 146

Relocation of R&D 147

Regulatory Climate 147

JAPAN 148

New Drug Approvals 148

Regulatory Climate 148

Relationship between Academia and Industry 149

Chapter-9: FUTURE DIRECTIONS

THERAPEUTIC VACCINES AS FIRST-LINE THERAPIES 150

THE ROLE OF BIOMARKERS 151

VACCINES AND CLINICAL TRIAL DESIGN 151

COMBINATION THERAPIES 152

To order this report:

Pharmaceutical Industry: Therapeutic Vaccines: The Global Market

More Market Research Report

Check our Company Profile, SWOT and Revenue Analysis!

Nicolas Bombourg Reportlinker Email: nbo@reportlinker.com US: (805)652-2626 Intl: +1 805-652-2626

SOURCE Reportlinker
Advertisement


Advertisement

You May Also Like

Advertisement
View All

Post your Comments

Comments should be on the topic and should not be abusive. The editorial team reserves the right to review and moderate the comments posted on the site.
User Avatar
* Your comment can be maximum of 2500 characters
I agree to the terms and conditions
s
Reportlinker Adds Actelion Ltd: PharmaVitae Profil...
S
Reportlinker Adds Pharmaceutical Licensing Overvie...